transthyretin-mediated amyloidosis

Alnylam Pharmaceuticals and collaborators this week published data from phase I trials of the siRNA-based transthyretin amyloidosis drugs ALN-TTR01 and ALN-TTR02 in the New England Journal of Medicine.

Alnylam Pharmaceuticals this week said that it has begun dosing patients in a phase I study of its siRNA-based transthyretin-mediated amyloidosis treatment ALN-TTR02.

Alnylam also released its first-quarter financial results, reporting higher losses and lower revenues.

Specifically, the designation is for the use of the drug against familial amyloidotic polyneuropathy, one of the predominant forms of the disease, Alnylam said.

The company also disclosed that it and partner Cubist Pharmaceuticals have decided to put on hold the development of a second-generation version of Alnylam's respiratory syncytial virus treatment, although no details regarding the decision were provided.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.